New study finds that inflammatory proteins in the colon increase incrementally with weight

October 10, 2018, Tufts University
New study finds that inflammatory proteins in the colon increase incrementally with weight
Credit: Pixabay

Studies in mice have demonstrated that obesity-induced inflammation contributes to the risk of colorectal cancer, but evidence in humans has been scarce. A new study shows that two inflammatory proteins in the colon increase in parallel with increasing weight in humans. An incremental rise in these pro-inflammatory proteins (called cytokines) was observed along the entire spectrum of subjects' weights, which extended from lean to obese individuals. In participants with obesity, there was evidence that two pre-cancerous cellular pathways known to be triggered by these cytokines were also activated.

The study, while modest in size, provides new evidence that obesity promotes cancer through inflammation. Secondary findings suggest that NSAIDS lower the levels of in the colon, regardless of a person's weight. The study is published online in advance of print in Cancer Epidemiology, Biomarkers & Prevention.

Led by Joel B. Mason, M.D., a gastroenterologist who studies nutrition and cancer prevention at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (HNRCA), the study included 42 Caucasian participants. Sixteen research participants were lean, with a BMI between 18.1 and 24.9, while 26 participants with obesity had a BMI ranging from 30.0 to 45.7. The participants were between the ages of 45 and 70 years of age and were undergoing routine screening colonoscopies at Tufts Medical Center.

Using blood samples and colonic biopsies, the researchers determined that the concentrations of two major cytokines rose in parallel with BMI. Cytokines are proteins that mediate and regulate immunity and inflammation, among other things. In addition to evidence that they can promote cancer risk in certain tissues, pro-inflammatory cytokines have been identified as actors in insulin resistance and diabetes, as well as inflammatory disorders such as arthritis.

In addition to the work analyzing cytokines, the research team studied differences in the mucosal transcriptome between the two sets of research participants, finding changes indicative of activation in two gene expression networks that are pivotal in the development of in the participants with obesity.

"Our results establish, for the first time, that concentrations in the colon of two major cytokines increase in concert with increasing BMI in humans. The increased concentrations are accompanied by changes in gene activation within the lining of the colon that are pro-cancerous in nature," said senior author Joel B. Mason, M.D., director of the Vitamins and Carcinogenesis Laboratory at the HNRCA.

In an effort to identify potential confounding factors, the research team determined that thirteen of the 42 study participants were also regular users of NSAIDs, such as aspirin and ibuprofen. The research team discovered that participants who took NSAIDs at least once per week, compared to those who did not, had lower levels of pro-inflammatory proteins in the colon. This pattern was consistent across the two BMI groups.

"Observational and clinical trials show aspirin can reduce the risk of colon cancer, but it continues to be controversial because of the risk of serious gastrointestinal bleeding. NSAIDs are probably working through multiple avenues, one of which is cytokines. Our observation underscores prior work that has suggested that some NSAIDs reduce the risk of colon cancer, presumed to occur through a reduction in colonic inflammation. Their use, however, has to be weighed against the potential adverse effects," said Mason.

The authors noted that the modest study size and the Caucasian population are limitations of the study, writing "given the cross-sectional nature of this study, the results cannot prove that the observed changes in the colonic transcriptome are due to the rise in cytokines...Observations from this study nevertheless underscore the potential contribution that the establishment of an inflammatory milieu in the colonic mucosa may play in explaining the enhanced risk of colon cancer due to obesity."

In the United States, is the third most common cancer and the second leading cause of death among cancers that affect both men and women, according to the CDC. The American Cancer Society reports that the overall lifetime risk of developing colorectal is about 1 in 22 for men and 1 in 24 for women.

The first author on the study is Anna C. Pfalzer, a Ph.D. graduate in biochemical and molecular nutrition from the Friedman School and former member of Mason's laboratory. Pfalzer is now at Vanderbilt University Medical Center. Joel Mason is also a professor at Tufts University School of Medicine and at the Friedman School of Nutrition Science and Policy at Tufts and a gastroenterologist at Tufts Medical Center.

Explore further: Identifying the mechanism in obesity's link to colon cancer

More information: Anna C Pfalzer et al, Incremental elevations of TNF-α and IL-6 in the human colon and pro-cancerous changes in the mucosal transcriptome accompany adiposity, Cancer Epidemiology Biomarkers & Prevention (2018). DOI: 10.1158/1055-9965.EPI-18-0121

Related Stories

Identifying the mechanism in obesity's link to colon cancer

April 30, 2018
In a recent new finding, doctoral candidates Wiecang Wang and Jianan Zhang, with their advisor Guodong Zhang in the department of food science at the University of Massachusetts Amherst, report that they have identified a ...

Breaking the link between obesity, gastrointestinal cancers

September 27, 2018
Studies have demonstrated a connection between obesity and a person's risk of developing colon and other gastrointestinal cancers. Now, scientists are investigating approaches that can break this relationship.

Soy lecithin NSAID combo drug protects against cancer with fewer side effects

May 30, 2018
When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSAID), they increased its anticancer properties and reduced ...

What role do inflammatory cytokines play in creating T cell exhaustion in cancer?

August 3, 2018
A better understanding of the role secreted inflammatory cytokines play in the tumor microenvironment that results in the differentiation of effector T cells into exhausted T cells points to possible approaches to improve ...

SMAD4 clue to colon cancer

July 6, 2018
Chronic inflammation is a predisposing condition for colorectal cancer, the third leading cause of cancer-related deaths in the United States.

Review: inflammation's role in obesity-colorectal cancer link

September 13, 2012
(HealthDay)—A new review summarizes the ways in which inflammation and altered metabolism are associated with colorectal cancer in obese individuals; the review was published online Sept. 3 in Obesity Reviews.

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.